Results 51 to 60 of about 2,872,365 (306)

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review

BMJ Open, 2018
Introduction The opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist ...
Brian Hutton, Beverley Shea, Kimberly Corace, David Moher, Danielle B Rice, Becky Skidmore, Kednapa Thavorn, Sheena Taha, Dianna Wolfe, Fatemeh Yazdi, Beth A Sproule, Melanie Willows, Patricia Poulin, Gary Garber, Amy Porath, Leila Esmaeilisaraji   +15 more
doaj   +1 more source

Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. [PDF]

Glob Health Econ Sustain
The incidence and mortality of human immunodeficiency viruses (HIVs) are rising in Eastern Europe and Central Asia (EECA), particularly among people who inject drugs. Opioid agonist therapies (OATs), such as methadone or buprenorphine, are the most effective treatments for opioid use disorder and serve as a key HIV-prevention strategy in EECA.
Liberman AR, Kurmanalieva A, Biibosunova DI, Shumskaya N, Ivasiy R, Bromberg DJ, Madden LM, Altice FL.   +7 more
europepmc   +3 more sources

PREDICTORS OF CRYSTAL METHAMPHETAMINE USE INITIATION OR RE-INITIATION AMONG PEOPLE RECEIVING OPIOID AGONIST THERAPY: A PROSPECTIVE COHORT STUDY

Drug and Alcohol Dependence, 2022
Background In the context of the ongoing opioid crisis in the United States and Canada, opioid agonist therapy (OAT) is the first-line treatment for opioid use disorder. However, there is growing concern regarding the increasing methamphetamine use among
Z. Cui, K. Hayashi, P. Bach, Hui-Ru Dong, M. Milloy, T. Kerr   +5 more
semanticscholar   +1 more source

A qualitative study on people with opioid use disorders’ perspectives on smoking and smoking cessation interventions

Frontiers in Psychiatry, 2023
IntroductionSmoking-related diseases are major contributors to disability and shorter life expectancy among opioid-dependent patients. Smoking prevalence is considerably higher for opioid-dependent persons than among the general population, and only a ...
Karl Trygve Druckrey-Fiskaaen, Karl Trygve Druckrey-Fiskaaen, Einar Furulund, Einar Furulund, Einar Furulund, Tesfaye Madebo, Tesfaye Madebo, Siv-Elin Leirvåg Carlsen, Lars T. Fadnes, Lars T. Fadnes, Torgeir Gilje Lid, Torgeir Gilje Lid, for ATLAS4LAR Study Group, Vibeke Bråthen Buljovcic, Jan Tore Daltveit, Karl Trygve Druckrey-Fiskaaen, Lars T. Fadnes, Trude Fondenes, Per Gundersen, Beate Haga Trettenes, Siv-Elin Leirvåg Carlsen, Mette Hegland Nordbotn, Maria Olsvold, Marianne Cook Pierron, Christine Sundal, Jørn Henrik Vold, Maren Borsheim Bergsaker, Eivin Dahl, Tone Lise Eielsen, Torhild Fiskå, Marianne Larssen, Torgeir Gilje Lid, Eirik Holder, Tesfaye Madebo, Ewa Joanna Wilk, Mari Thoresen Soot   +35 more
doaj   +1 more source

The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study.

Clinical Infectious Diseases, 2021
BACKGROUND Evidence that opioid agonist therapy (OAT) is associated with increased odds of hepatitis C virus (HCV) treatment initiation among people who use drugs (PWUD) is emerging.
Sofia R. Bartlett, S. Wong, A. Yu, M. Pearce, J. MacIsaac, Susan Nouch, P. Adu, J. Wilton, H. Samji, Emilia Clementi, Hector Velásquez, Dahn Jeong, M. Binka, M. Alvarez, J. Wong, J. Buxton, M. Krajden, N. Janjua   +17 more
semanticscholar   +1 more source

The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia. [PDF]

Clin Infect Dis
Abstract Background People prescribed opioid agonist therapy (OAT) are a key population for hepatitis C virus (HCV) elimination. Health service engagement associated with OAT provision may facilitate hepatitis C testing and treatment.
Griffin S, Asselin J, Wilkinson AL, Traeger MW, Pedrana A, Winter RJ, Thompson AJ, Penn M, Dimech W, Donovan B, Hellard M, Stoové M.   +11 more
europepmc   +3 more sources

Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series

Addiction Science & Clinical Practice, 2023
Background Hospitalizations are a vital opportunity for the initiation of life-saving opioid agonist therapy (OAT) for patients with opioid use disorder.
John P. Murray, Geoffrey Pucci, George Weyer, Mim Ari, Sarah Dickson, Angela Kerins   +5 more
doaj   +1 more source

Diels–Alder Adducts of Morphinan-6,8-Dienes and Their Transformations

Molecules, 2022
6,14-ethenomorphinans are semisynthetic opiate derivatives containing an ethylene bridge between positions 6 and 14 in ring-C of the morphine skeleton that imparts a rigid molecular structure.
János Marton, Anikó Fekete, Paul Cumming, Sándor Hosztafi, Pál Mikecz, Gjermund Henriksen   +5 more
doaj   +1 more source

Trajectories of retention in opioid agonist therapy and overdose risk during a communitywide overdose epidemic in a Canadian setting

American Journal of Preventive Medicine, 2021
Introduction: Retention in opioid agonist therapy (OAT) has consistently been linked with improved outcomes among people with opioid use disorder (PWOUD). However, less is known about the links between patterns of engagement in OAT over the long term and
M. Socías, Hui-Ru Dong, E. Wood, S. Nolan, K. Hayashi, T. Kerr, M. Milloy   +6 more
semanticscholar   +1 more source

BUPRENORPHINE IN OPIOID ADDICTION TEREATMENT: STUDIES WITH METHADONE COMPARISON

Psychiatry and Clinical Psychopharmacology, 2021
Methadone maintenance treatment is the most widely used pharmacological treatment approach for opioid addiction in many countries. In spite of many benefits that was gained after the usage of full agonist methadone, especially high numbers of patients ...
E.Cüneyt Evren, Defne Tamar, Bilge Babayağmur, Duran Çakmak   +3 more
doaj